- Home
- ANNX vs YSG Comparison
ANNX vs YSG Comparison
Compare ANNX & YSG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANNX
- YSG
- Stock Information
- Founded
- ANNX 2011
- YSG 2016
- Country
- ANNX United States
- YSG China
- Employees
- ANNX N/A
- YSG N/A
- Industry
- ANNX Biotechnology: Pharmaceutical Preparations
- YSG Package Goods/Cosmetics
- Sector
- ANNX Health Care
- YSG Consumer Discretionary
- Exchange
- ANNX Nasdaq
- YSG Nasdaq
- Market Cap
- ANNX 362.4M
- YSG 362.5M
- IPO Year
- ANNX 2020
- YSG 2020
- Fundamental
- Price
- ANNX $1.82
- YSG $4.71
- Analyst Decision
- ANNX Strong Buy
- YSG
- Analyst Count
- ANNX 5
- YSG 0
- Target Price
- ANNX $18.67
- YSG N/A
- AVG Volume (30 Days)
- ANNX 1.8M
- YSG 277.3K
- Earning Date
- ANNX 05-12-2025
- YSG 05-21-2025
- Dividend Yield
- ANNX N/A
- YSG N/A
- EPS Growth
- ANNX N/A
- YSG N/A
- EPS
- ANNX N/A
- YSG N/A
- Revenue
- ANNX N/A
- YSG $464,908,550.00
- Revenue This Year
- ANNX N/A
- YSG $16.55
- Revenue Next Year
- ANNX N/A
- YSG $13.17
- P/E Ratio
- ANNX N/A
- YSG N/A
- Revenue Growth
- ANNX N/A
- YSG N/A
- 52 Week Low
- ANNX $1.76
- YSG $2.28
- 52 Week High
- ANNX $7.85
- YSG $6.13
- Technical
- Relative Strength Index (RSI)
- ANNX 29.68
- YSG 49.82
- Support Level
- ANNX $2.18
- YSG $4.50
- Resistance Level
- ANNX $2.75
- YSG $5.73
- Average True Range (ATR)
- ANNX 0.24
- YSG 0.64
- MACD
- ANNX -0.03
- YSG -0.09
- Stochastic Oscillator
- ANNX 3.02
- YSG 23.24
About ANNX Annexon Inc.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.
About YSG Yatsen Holding Limited
Yatsen Holding Ltd is engaged in the retail business of beauty products, skincare items, and other cosmetic products. The Group's principal operations are currently organized into three segments on a product category basis, namely Color Cosmetics Brands, Skincare Brands, and others. The company's majority of revenue is generated from sales of Color Cosmetics Brands.